Tiziana Life Sciences (NASDAQ: TLSA) — Perfil da empresa, notícias e dados financeiros
Tiziana Life Sciences develops therapies targeting autoimmune and cancer diseases, aiming to improve patient outcomes through innovation.
Tiziana Life Sciences
Tiziana Life Sciences (NASDAQ:TLSA) is a biotechnology firm dedicated to discovering and developing novel therapies that can potentially transform the treatment of diseases in fields such as immunology and oncology. At the heart of its operations are projects targeting the modulation of the human immune system, aiming at diseases that currently have limited treatment options. Their objectives include advancing their pipeline of therapeutic candidates through clinical trials with the ultimate goal of bringing transformative treatments to market. The company's research focuses on leveraging its expertise in monoclonal antibodies and small molecules to potentially improve patient outcomes in areas such as multiple sclerosis, Crohn's disease, and cancer.
Resumo
Operações
Produtos e/ou serviços de Tiziana Life Sciences
- Anti-Claudin 18.2 (TCN): Their lead drug candidate targeting Claudin 18.2 expressing tumors, which are found in various cancers including gastric, esophageal, pancreatic, and non-small cell lung cancer.
- Anti-CD38 (TSL-272): This drug candidate targets CD38, a protein expressed on the surface of multiple myeloma and other hematological malignancies.
- Anti-EphA2 (TSL-118): This drug candidate targets EphA2, a receptor tyrosine kinase overexpressed in several solid tumors.
- Anti-Fc?RIIb (TSL-132): This drug candidate targets Fc?RIIb, an inhibitory receptor on macrophages that can be exploited to enhance antibody-dependent cellular cytotoxicity (ADCC) of therapeutic antibodies.
- Discovery and Development Efforts: Tiziana Life Sciences has a pipeline of other discovery and development efforts targeting various diseases.
- Collaboration Partnerships: They partner with other biotechnology and pharmaceutical companies to leverage their expertise and resources.
equipe executiva do Tiziana Life Sciences
- Gabriele Marco Antonio CerroneFounder & Executive Chairman
- Keeren ShahCOO & CFO
- Ivor R. ElrifiCEO & Executive Director
- William Edward TenteChief Regulatory Officer
- Richard K. KimChief Medical Officer
- Napoleone FerraraMember of Scientific Advisory Board
Principais indicadores financeiros
Resultados divulgados pela Tiziana Life Sciences, em USD.
- Cap. de mercado
- 111 mi
- Receita (TTM)
- -3,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -21,1 mi | -18,4 mi | |
| 0 | -15,8 mi | -11,9 mi | |
| 0 | -18 mi | -17,7 mi | |
| 0 | -14,6 mi | -15,4 mi |